BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9279533)

  • 1. Effect of glibenclamide on insulin release at moderate and high blood glucose levels in normal man.
    Ligtenberg JJ; Venker CE; Sluiter WJ; Reitsma WD; Van Haeften TW
    Eur J Clin Invest; 1997 Aug; 27(8):685-9. PubMed ID: 9279533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
    Clark HE; Matthews DR
    Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
    van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
    Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation.
    Abbink EJ; van der Wal PS; Sweep CG; Smits P; Tack CJ
    Diabetes Metab Res Rev; 2004; 20(6):466-71. PubMed ID: 15386823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of blood glucose lowering effect of a sulfonylurea when coadministered with an ACE inhibitor: results of a glucose-clamp study.
    Rave K; Flesch S; Kühn-Velten WN; Hompesch BC; Heinemann L; Heise T
    Diabetes Metab Res Rev; 2005; 21(5):459-64. PubMed ID: 15915547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gliclazide mainly affects insulin secretion in second phase of type 2 diabetes mellitus.
    Ligtenberg JJ; Reitsma WD; van Haeften TW
    Horm Metab Res; 2001 Jun; 33(6):361-4. PubMed ID: 11456286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia.
    Rosak C; Haupt E; Walter T; Werner J
    Diabetes Nutr Metab; 2002 Jun; 15(3):143-51. PubMed ID: 12173728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.
    Gutniak MK; Juntti-Berggren L; Hellström PM; Guenifi A; Holst JJ; Efendic S
    Diabetes Care; 1996 Aug; 19(8):857-63. PubMed ID: 8842604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetes.
    Hanefeld M; Haffner SM; Menschikowski M; Koehler C; Temelkova-Kurktschiev T; Wildbrett J; Fischer S
    Diabetes Res Clin Pract; 2002 Mar; 55(3):221-7. PubMed ID: 11850098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3.
    Tuomi T; Honkanen EH; Isomaa B; Sarelin L; Groop LC
    Diabetes Care; 2006 Feb; 29(2):189-94. PubMed ID: 16443858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of pancreatic beta-cell secretion in Type 2 diabetic patients treated with gliclazide and glibenclamide.
    van der Wal PS; Heine RJ
    Diabetes Res Clin Pract; 2001 May; 52(2):103-11. PubMed ID: 11311964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of glibenclamide on insulin secretion at normal glucose concentrations.
    Riefflin A; Ayyagari U; Manley SE; Holman RR; Levy JC
    Diabetologia; 2015 Jan; 58(1):43-9. PubMed ID: 25297572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the oral hypoglycaemic sulphonylurea glibenclamide, a blocker of ATP-sensitive potassium channels, on walking distance in patients with intermittent claudication.
    Mortensen UM; Nielsen-Kudsk JE; Sondergaard HM; Jakobsen P; Jensen BS; Schmitz O; Nielsen TT
    Diabet Med; 2006 Mar; 23(3):327-30. PubMed ID: 16492219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of glimepiride and glyburide on glucose counterregulation and recovery from hypoglycemia.
    Szoke E; Gosmanov NR; Sinkin JC; Nihalani A; Fender AB; Cryer PE; Meyer C; Gerich JE
    Metabolism; 2006 Jan; 55(1):78-83. PubMed ID: 16324923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide.
    Hartmann D; Korn A; Komjati M; Heinz G; Haefelfinger P; Defoin R; Waldhäusl WK
    Br J Clin Pharmacol; 1990 Aug; 30(2):245-52. PubMed ID: 2119677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics and pharmacokinetics of intravenous glibenclamide in Caucasian and Chinese patients with type-2 diabetes.
    Jönsson A; Chan JC; Rydberg T; Vaaler S; Hallengren B; Cockram CS; Critchley JA; Melander A
    Eur J Clin Pharmacol; 2000 Jan; 55(10):721-7. PubMed ID: 10663449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of insulinotrophic actions of nateglinide with glibenclamide dissociated from absorption in conscious dogs.
    Okamoto M; Ogihara N; Kawamura W; Ebihara S; Takiguchi K; Morita T; Uchida R; Yamaguchi J; Sakai T; Okuda Y; Hayashi Y; Arakawa Y; Kikuchi M
    Metabolism; 2002 May; 51(5):575-81. PubMed ID: 11979388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glyburide enhances the responsiveness of the beta-cell to glucose but does not correct the abnormal patterns of insulin secretion in noninsulin-dependent diabetes mellitus.
    Shapiro ET; Van Cauter E; Tillil H; Given BD; Hirsch L; Beebe C; Rubenstein AH; Polonsky KS
    J Clin Endocrinol Metab; 1989 Sep; 69(3):571-6. PubMed ID: 2503533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
    Cuthbertson J; Patterson S; O'Harte FP; Bell PM
    Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.